BCIQ Profiles

Company Profile Report

Azar’s political play with drug importation

Editor’s Commentary: Why the HHS drug importation plan is a bad idea

The drug importation policy announced by Alex Azar last week is a political stunt, aimed at generating headlines at a time when the HHS secretary seems desperate to demonstrate to Donald Trump and the media that he’s fulfilling the president’s pledges to lower drug prices.

In fact, as Azar knows, importation will have a negligible effect on access to drugs.

Opening the door to importation as a price control tactic will, however, create precedents that will damage FDA, and consequently hurt biomedical innovators and patients.

The new policy would allow importation of

Read the full 920 word article

How to gain access

Continue reading with a
two-week free trial.